Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

Alpha1-antitrypsin Deficiency Clinical Trial

Official title:

Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00161707
• Other study ID #: 410103
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 7, 2003
• Est. completion date: October 1, 2003

Study information

• Verified date: April 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this randomized, double-blind, placebo-controlled study is to evaluate the short-term safety of inhaled recombinant alpha 1-antitrypsin (rAAT) in subjects with alpha 1-antitrypsin deficiency. The subjects are randomized to receive placebo or one of 4 doses of rAAT. The 4 doses are tested in a consecutive manner from lowest to highest.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: October 1, 2003
• Est. primary completion date: October 1, 2003
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female 18 years of age or older

• Endogenous plasma AAT levels < 11 µM (< 80 mg/dL)

• Baseline forced expiratory volume at one second (FEV1) that is >= 50% of predicted, measured 30 minutes after a short-acting inhaled bronchodilator

• Baseline arterial oxygen percent saturation (SaO2) within the normal limits for the individual study site

• For subjects receiving an inhaled corticosteroid, ß-2 agonist (eg, albuterol via metered dose inhaler [MDI]) or anticholinergic bronchodilator (eg, ipratropium bromide), treatment on a stable dose for at least 14 days prior to randomization

• If female of childbearing potential, negative urine pregnancy test within 3 days prior to randomization and agreement to employ adequate birth control measures

• No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed no more than 7 days prior to randomization

• Baseline laboratory results, obtained no more than 7 days prior to randomization, meeting the following criteria:

• Serum aspartate transaminase (AST) and alanine transaminase (ALT) <= 2 times upper limit of normal range (ULN)

• Serum total bilirubin <= 2 times ULN

• < 2+ proteinuria on urine dipstick

• Serum creatinine <= 1.5 times ULN

• Absolute neutrophil count >= 1500 cells/mm3

• Hemoglobin >= 10.0 g/dL

• Platelet count >= 100,000/mm3

• Signed informed consent

Exclusion Criteria:

• Clinically significant pulmonary impairment, other than emphysema and/or chronic bronchitis

• Clinically significant cardiac, hemostatic, or neurologic impairment, or other significant medical condition that, in the opinion of the investigator, would affect subject safety or compliance

• Psychiatric or cognitive disturbance or illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance

• Acute exacerbation of emphysema (as defined in Section 8.5.10) within 28 days prior to randomization

• Pregnancy or lactation

• Known history of allergy to yeast products

• Medical history precluding the use of epinephrine or other rescue medication for treatment of anaphylaxis

• Use of antihistamines within 7 days prior to randomization

• Use of oral steroids, beta-blockers, or tricyclic antidepressants within 28 days prior to randomization

• Use of another investigational drug or investigational device within 28 days prior to randomization

• Any upper or lower respiratory infection within 28 days prior to randomization

Related Conditions & MeSH terms

• Alpha 1-Antitrypsin Deficiency
• Alpha1-antitrypsin Deficiency

Intervention

Drug:
• Aerosolized, Recombinant Alpha 1-Antitrypsin

Locations

Country	Name	City	State
United States	Cleveland Clinic Foundation, Department of Pulmonary and Critical Care Medicine	Cleveland	Ohio
United States	National Jewish Medical and Research Center	Denver	Colorado
United States	Shands Hospital at the University of Florida	Gainesville	Florida
United States	The University of Texas Health Science Center at Tyler	Tyler	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Baxalta now part of Shire	Arriva Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants who develop antibodies to Recombinant Alpha 1-Antitrypsin (rAAT)		6 weeks after the first inhalation of study drug